logo

Brainstorm Cell Therapeutics Inc. (BCLI)



Trade BCLI now with
  Date
  Headline
5/16/2022 7:47:42 AM BrainStorm Cell Therapeutics Q1 Loss $5.4 Mln Vs. Loss $6.7 Mln Prior Year
5/4/2022 6:01:40 AM BrainStorm Announces Presentation Of NurOwn Exosome Preclinical Data
3/28/2022 7:18:22 AM BrainStorm Cell Therapeutics FY Loss Per Share $0.68 Vs Loss $1.07 Last Eyar
12/27/2021 7:02:24 AM BrainStorm Cell Therapeutics : FDA Authorizes Further NurOwn Dosing Under Expanded Access Program
11/29/2021 7:37:58 AM BrainStorm Cell Announces Presentation Of New Analyses From Phase 3 Trial Of NurOwn In ALS
11/15/2021 7:12:53 AM BrainStorm Cell Therapeutics Q3 Net Loss $5.3 Mln Vs. Net Loss $4.5 Mln Last Year
10/18/2021 7:31:52 AM BrainStorm Announces Scientific Presentation Of NurOwn Exosome Preclinical ARDS Data
10/14/2021 7:09:08 AM BrainStorm : Phase 2 Clinical Trial Data Of NurOwn In Progressive MS Will Be Presented
10/1/2021 7:32:07 AM BrainStorm To Present Phase 2 Progressive MS Study Results In Oral Presentation At 37th Congress Of ECTRIMS
4/26/2021 7:19:58 AM BrainStorm Q1 Loss Per Share $0.19 Vs $0.32 Last Year
3/24/2021 7:12:49 AM BrainStorm Reports Positive Data In Phase 2 Study Evaluating NurOwn As Treatment For Progressive MS; Stock Surges
2/9/2021 9:03:05 AM BrainStorm Says Pleased With FDA Type C Meeting Outcome And Guidance On Requirements For Future Semi-automated Process